In a June 4th, 2024 press release, Johnson & Johnson (NYSE: JNJ) announced an investor conference call on July 17th at 8:30 a.m. (Eastern Time) to review second-quarter results. The webcast and presentation materials will be available on their website, with a replay accessible three hours after the call. The replay will remain available until August 14th at midnight. The press release will be available at 6:45 a.m. on the day of the call.
Market Cap
With a market cap of $363.43 billion as of July 2024, Johnson & Johnson ranks as the world’s 28th most valuable company, according to companiesmarketcap.com.
Dividend Information 
Johnson & Johnson offers a 3.29% dividend yield with an annual dividend of $4.96. The quarterly payout has a 32.87% ratio and has grown for 62 years, increasing by 5.02%. The next ex-dividend date is May 20, 2024. The company has a buyback yield of 6.73% and a shareholder yield of 10.03%.
Recent Development At Johnson & Johnson 
Here are the latest updates from Johnson & Johnson:
– Johnson & Johnson finalizes purchase of Proteologix, Inc.
– Johnson & Johnson completes acquisition of Shockwave Medical.
– Johnson & Johnson enhances atopic dermatitis pipeline by acquiring Yellow Jersey Therapeutics and NM26.
– Johnson & Johnson files for FDA approval of TREMFYA® (guselkumab) to treat moderate to severe Crohn’s disease.
– Johnson & Johnson demonstrates innovation and leadership in rheumatology at EULAR 2024 Congress.
– Johnson & Johnson’s pivotal study of seltorexant shows significant improvements in depressive symptoms and sleep disturbances.
Q1 Earnings Report Recap 
In Q1 2024, Johnson & Johnson’s sales increased 2.3% to $21.4 billion. GAAP earnings hit $5.4 billion, with EPS at $2.20, a significant turnaround from the previous year’s loss. Adjusted earnings rose to $6.6 billion, with a 12.4% increase in adjusted EPS to $2.71. CEO Joaquin Duato highlighted the robust performance, crediting their strategic focus and innovative progress across healthcare.
Q2 Earnings Report Analyst Forecast
For Q2 2024, Zacks Consensus Estimate projects Johnson & Johnson’s EPS at $2.71, with a range of $2.68 to $2.74, showing a year-over-year decline of 3.21% from $2.80. Sales are estimated at $22.38 billion, with forecasts between $22.28 billion and $22.48 billion, marking a 12.35% decrease from last year’s $25.53 billion.
Investing.com projects Johnson & Johnson (NYSE: JNJ) to hit an EPS of $2.72 and revenue of $22.34 billion.
Tradingview.com projects Johnson & Johnson (NYSE: JNJ) to hit an EPS of $2.71 with revenue of $22.33 billion.
Technical Analysis 
– Johnson & Johnson chart shows a down trendline breakout at $148.95 on Tradingview.
– If breakout holds, price could rally to $152.00; if $152.00 is breached, target $154.40.
– If breakout fails, price may drop to $145.06; if $145.06 is breached, target $140.12.
Apply Risk Management
Conclusion
In conclusion, Johnson & Johnson’s robust performance in Q1 2024, with a 2.3% increase in sales to $21.4 billion and a significant turnaround in GAAP earnings, showcases its strategic focus and innovative progress. Despite a projected slight decline in Q2 2024 EPS and sales, the company’s strong dividend history and recent acquisitions position it well for future growth. Overall, Johnson & Johnson continues to demonstrate resilience and leadership in the healthcare industry, maintaining a positive outlook.
Source:
https://companiesmarketcap.com/johnson-and-johnson/marketcap/#google_vignette
https://stockanalysis.com/stocks/jnj/dividend/
https://images.app.goo.gl/EQrEab3oEwnjWbwb8
https://www.investor.jnj.com/financials/quarterly-results/default.aspx
https://www.zacks.com/stock/quote/JNJ/detailed-earning-estimates
https://www.investing.com/equities/johnson-johnson-earnings
